Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- FemPulse™, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today that the Company’s pivotal...
-
Independent investigators from the University of Pisa presented new data at the 2026 European Congress of Radiology (ECR) Ultrasound follow-up documented predictable scaffold bioresorption and...
-
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile
-
The Lancet Microbe publishes SNIPR001 Phase 1: safe, gut‑restricted, microbiome stable; Phase 1b HSCT trial >50% enrolled.
-
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE...
-
AtaiBeckley today announced topline results from its Phase 2a study evaluating EMP‑01 (oral R‑MDMA) in adults with Social Anxiety Disorder.
-
Results of Phase 2b clinical trial demonstrating stem cell therapy improved condition of patients with aging frailty published in Cell Stem Cell journal.
-
Austin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Pharmacovigilance Market size is estimated at USD 8.91 billion in 2025 and is expected to reach USD 24.69 billion by 2035,...
-
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at...